JP2024534488A5 - - Google Patents
Info
- Publication number
- JP2024534488A5 JP2024534488A5 JP2024517157A JP2024517157A JP2024534488A5 JP 2024534488 A5 JP2024534488 A5 JP 2024534488A5 JP 2024517157 A JP2024517157 A JP 2024517157A JP 2024517157 A JP2024517157 A JP 2024517157A JP 2024534488 A5 JP2024534488 A5 JP 2024534488A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245162P | 2021-09-16 | 2021-09-16 | |
| US63/245,162 | 2021-09-16 | ||
| US202163250177P | 2021-09-29 | 2021-09-29 | |
| US63/250,177 | 2021-09-29 | ||
| US202163293619P | 2021-12-23 | 2021-12-23 | |
| US63/293,619 | 2021-12-23 | ||
| US202263348876P | 2022-06-03 | 2022-06-03 | |
| US63/348,876 | 2022-06-03 | ||
| PCT/US2022/076516 WO2023044398A1 (en) | 2021-09-16 | 2022-09-15 | Dosing of muscle targeting complexes for treating dystrophinopathies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024534488A JP2024534488A (ja) | 2024-09-20 |
| JPWO2023044398A5 JPWO2023044398A5 (https=) | 2025-09-25 |
| JP2024534488A5 true JP2024534488A5 (https=) | 2025-09-25 |
Family
ID=85603633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024517157A Pending JP2024534488A (ja) | 2021-09-16 | 2022-09-15 | ジストロフィノパチーを処置するための筋標的化複合体の投与 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250018050A1 (https=) |
| EP (1) | EP4401777A4 (https=) |
| JP (1) | JP2024534488A (https=) |
| KR (1) | KR20240058160A (https=) |
| AU (1) | AU2022345986A1 (https=) |
| CA (1) | CA3230451A1 (https=) |
| IL (1) | IL311507A (https=) |
| MX (1) | MX2024003373A (https=) |
| WO (1) | WO2023044398A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| IL309936A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of dystrophinopathy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US20250339553A1 (en) | 2022-04-15 | 2025-11-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025255283A1 (en) * | 2024-06-07 | 2025-12-11 | Dyne Therapeutics, Inc. | Dosing of muscle targeting complexes for treating facioscapulohumeral muscular dystrophy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2906812A1 (en) * | 2013-03-15 | 2014-09-18 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
| WO2017192679A1 (en) * | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd. | Methods and compositions of biologically active agents |
| US20190330626A1 (en) * | 2016-07-15 | 2019-10-31 | Ionis Pharmaceuticals, Inc. | Compounds and methods for use in dystrophin transcript |
| EP3829595A4 (en) * | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| JP7780691B2 (ja) * | 2020-01-10 | 2025-12-05 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| AU2021206234A1 (en) * | 2020-01-10 | 2022-09-01 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
-
2022
- 2022-09-15 IL IL311507A patent/IL311507A/en unknown
- 2022-09-15 WO PCT/US2022/076516 patent/WO2023044398A1/en not_active Ceased
- 2022-09-15 CA CA3230451A patent/CA3230451A1/en active Pending
- 2022-09-15 EP EP22870961.4A patent/EP4401777A4/en active Pending
- 2022-09-15 JP JP2024517157A patent/JP2024534488A/ja active Pending
- 2022-09-15 MX MX2024003373A patent/MX2024003373A/es unknown
- 2022-09-15 AU AU2022345986A patent/AU2022345986A1/en active Pending
- 2022-09-15 KR KR1020247012043A patent/KR20240058160A/ko active Pending
- 2022-09-15 US US18/692,415 patent/US20250018050A1/en active Pending